Quipt Home Medical (QIPT)
(Delayed Data from NSDQ)
$2.97 USD
-0.04 (-1.33%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $2.96 -0.01 (-0.34%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Quipt Home Medical Corp. (QIPT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.96 | $12.03 | $2.50 | 164.45% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Quipt Home Medical Corp. comes to $7.96. The forecasts range from a low of $2.50 to a high of $12.03. The average price target represents an increase of 164.45% from the last closing price of $3.01.
Analyst Price Targets (6 )
Broker Rating
Quipt Home Medical Corp. currently has an average brokerage recommendation (ABR) of 1.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.57 a month ago based on seven recommendations.
Of the six recommendations deriving the current ABR, five are Strong Buy, representing 83.33% of all recommendations. A month ago, Strong Buy represented 85.71%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 6 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 0 |
ABR | 1.67 | 1.67 | 1.57 | 1.67 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/20/2024 | The Benchmark Company | William Sutherland | Strong Buy | Strong Buy |
5/17/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
5/17/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/17/2024 | Raymond James Ltd. | Rahul Sarugaser | Strong Sell | Strong Sell |
4/11/2024 | Canaccord Genuity | Richard Close | Strong Buy | Strong Buy |
2/15/2024 | Leede Jones Gable | Douglas W Loe | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.67 |
ABR (Last week) | 1.67 |
# of Recs in ABR | 6 |
Average Target Price | $7.96 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 163 of 252 |
Current Quarter EPS Est: | 0.02 |